Skip to main content

Child Poisonings From Eye Drops, Nose Sprays


October 25, 2012 — Over-the-counter eyedrops and nose sprays contain powerful drugs that are poisonous in surprisingly small amounts if swallowed, the FDA warns.
Unwary parents often leave these products within easy reach of curious children. From 1997 through 2009, eyedrops injured more than 4,500 children under the age of 5 and nasal sprays injured more than 1,100, according to the U.S. Consumer Product Safety Commission (CPSC).
Injury reports show that children can easily open the products, which do not come in child-resistant packages.
The drugs are surprisingly powerful. Swallowing less than a fifth of a teaspoon can seriously harm a child, the FDA says.
The eyedrops in question soothe redness by causing blood vessels in the eye to constrict. Visine is a popular brand; there are many generic versions. Nose drops work in a similar way, tightening blood vessels in the nose. Afrin, Dristan, and Mucinex are popular brands, and there are many generic versions.
The products contain the active ingredients tetrahydrozoline, naphazoline, or oxymetazoline.
All three drugs are in the class of drugs called imidazolines. When placed in the eye or nose as directed, the drugs only affect that part of the body. But if swallowed, they quickly have effects throughout the body.
"Generally, symptoms can occur in as little as one hour, peaking at eight hours, and resolving after 12-36 hours," a CPSC briefing paper notes. "Even though the symptoms resolve in a relatively short amount of time, ingestion of imidazolines can result in severe life-threatening consequences, such as decreased breathing, decreased heart rate, and loss of consciousness that require hospitalization to ensure recovery."
The CPSC has proposed a new rule requiring child-resistant packaging for these products. That rule has yet to be finalized. Even when it's final, the rule will give manufacturers at least a year to comply. Meanwhile, many homes have at least one of the products in medicine cabinets.
To avoid accidental poisonings, the FDA says parents and caregivers should:
  • Store medicines in a safe location that is too high for young children to reach or see.
  • Never leave medicines or vitamins out on a kitchen counter or a child's bedside.
  • If a medicine bottle has a safety cap, relock it each time you use it.
  • Remind babysitters, houseguests, and visitors to keep purses, bags, or coats that have medicines in them away and out of sight when they are in your home.
  • Avoid taking medicines in front of young children because they like to mimic adults.
The FDA lists several specific products in its warning. Here's the list, which includes some but by no means all store and generic brands:
Products containing tetrahydrozoline
Products containing naphazoline
Products containing oxymetazoline
Visine Original
Visine A
Visine L.R.
Visine A.C.
Ak-Con Ophthalmic Solution
12 Hour Nasal Decongestant Nasal Spray
Visine Advanced Relief
Napha Forte Ophthalmic Solution
Afrin Extra Moisturizing Nasal Spray
Visine Totality
Naphazoline HCl Ophthalmic Solution
Afrin No Drip Severe Congestion Nasal Spray
Visine Maximum Redness Relief Formula
All Clear Ophthalmic Solution
Afrin No Drip Sinus Nasal Spray
Walgreens Redness Reliever Advanced Eye Ophthalmic Solution
All Clear AR Maximum Strength Ophthalmic Solution
Afrin No Drip Sinus Extra Moisturizing Nasal Spray
Tyzine Nasal Spray
Opcon-A Ophthalmic Solution
Afrin Original Nasal Spray
GNP Original Eye Drops
Naphcon A Ophthalmic Solution
Afrin Severe Congestion Nasal Spray
Opti-clear Ophthalmic Solution
Walgreens Eye Allergy Relief Drops
Dristan 12 Hour Nasal Spray
Tetrahydrozoline HCl Ophthalmic Solution

Equaline 12 Hour Nasal Spray
Today’s Health Original Eye Drops

Equaline 12 Hour Extra Moisturizing Nasal Spray
Leader Eye Drops Regular Formula Ophthalmic Solution

Equate Nasal Spray


GNP 12 Hour Nasal Spray


GNP 12 Hour No Drip Nasal Spray


GoodSense 12 Hour Nasal Spray


Leader 12 Hour Nasal Spray


Maximum Strength Nasal Decongestant Nasal Spray


Mucinex Full Force Nasal Spray


Mucinex Moisture Nasal Spray


Nasal Relief Spray


Neo-Synephrine 12 Hour Nasal Spray


Publix Nasal Spray


Select Brand Nasal Spray


Sinex Nasal Spray


Sudafed OM Nasal Spray


Today’s Health Nasal Relief Nasal Spray


Tope Care 12 Hour Nasal Spray


Walgreens Anefrin Nasal Spray
SOURCES:
FDA news release.
FDA web site.
CPSC web site.
CPSC: "Proposed PPPA Rule Requiring Child-Resistant Packaging for Imidazolines."

Comments

Post a Comment

Popular posts from this blog

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...
Post a Comment
Read more

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

Missing Data Lead FDA Panel to Vote Against Rivaroxaban for ACS May 23, 2012 (Updated May 24, 2012) (Silver Spring, Maryland) — The missing data issues plaguing the ATLAS ACS 2 TIMI 51 trial of the factor Xa inhibitor rivaroxaban (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the FDA Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting, the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus clopidogrel, or ticlopidine. Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the ATLAS ACS TIMI 46 phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the risk of bleeding and intracranial hemorrhage, but the studies were hindered by early patient withdrawals and missing data. We Don't Know What We're Missing Based on the ATLAS ACS 2 results, FDA reviewer Dr Karen Hicks recommended approval of rivaroxaban for the requested indications except all-cause mortality. However, another FDA reviewer, Dr Thomas Marciniak, was adamant that the trial results are not interpretable because about 12% of the patients had incomplete follow-up, far higher than the 1% to 1.5% differences in the end-point rates between rivaroxaban and placebo. A total of 1294 subjects discontinued the trial prematurely, and the company was only able to contact 183, of which 177 were confirmed to be alive. Because of the patient dropouts, the company adopted a "modified intention-to-treat analysis," whereby patients were observed for 30 days after randomization or the global end date for the trial, instead of observing all the patients until the end of the trial as the FDA originally suggested. Marciniak criticized the sponsor's efforts to follow the patients and said that three patient deaths not counted in the modified intention-to-treat analysis may just be the "tip of the iceberg." Because the percentage of patients whose ultimate vital status remains unknown is much greater than the reported differences in mortality rates, the claimed mortality benefits are not reliable. The majority of the panel sided with Marciniak. For example, Dr Sanjay Kaul (University of California, Los Angeles) voted "no" because "there was enough uncertainty in the quality and robustness of the data that dissuaded me from voting yes. . . . The 'missingness' of the data doesn't invalidate it, but it certainly makes it hard to infer [the conclusion]." Dr Steven Nissen (Cleveland Clinic, OH) said that the decision to use the modified intention-to-treat analysis had a "profound impact" on the interpretability of the data. "It's saying we don't care what happens after 30 days, [and] that colored the trial in ways we couldn't recover from." Given the risk of major bleeding, "I want to see better evidence that this strategy of adding an Xa inhibitor or a direct thrombin inhibitor or something else to a good antiplatelet agent is robustly better for the patient," Nissen said. He recommends that the companies run a new trial of the 2.5 twice-daily dose of rivaroxaban using a strict intention-to-treat approach, but, he said, "I don't expect the death benefit to be too robust." Several panelists said they were concerned that the patients who dropped out of the trial were disproportionately likely to have a bleeding event, which led them to quit the trial, or a "protopathic" event, as statistician Dr Scott Emerson (University of Washington, Seattle) put it. "We're worried that an impending event is what is changing their behavior. We see that all the time in clinical trials--that regularly measured end points do not pick up [all of] the events," he said. He said that since the company was only able to contact 183 of the over 1200 patients who dropped out, it is possible that the dropouts skew the outcomes comparison of the trial. "Differential event rates after dropout are the number-one thing we're afraid of, so you have to explore it" in a statistical sensitivity analysis of the potential impact of these unknown outcomes. "It would not surprise me if, at the end of the day, these data did not hold up under a proper sensitivity analysis," he said. "What I want to know is, among the people who had events, how differential was the follow-up, but I can tell you by just looking at it, there was a very slightly different amount of follow-up of the people in the treatment arm. But I don't know whether everyone in the treatment arm was cured and they were trekking in the Himalayas and everyone in the placebo arm went home to die. I don't know that that's not the case." Dr Maury Krantz (University of Colorado, Denver) voted in favor of approval but said he does not know how rivaroxaban would perform in general clinical practice, especially when used with aspirin and clopidogrel. "I felt very much torn by this. This isn't a simple paradigm shift. It means going to triple therapy, which is really a three-headed monster in many ways. I think that what you're going to see in practice, if this is not done carefully with the proper labeling and secondary studies, is really dramatic magnification of bleeding and perhaps minimization of the efficacy benefit."

May 23, 2012   (Updated May 24, 2012)  (Silver Spring, Maryland)  —  The missing data issues plaguing the  ATLAS ACS 2 TIMI 51   trial of the factor Xa inhibitor  rivaroxaban  (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the  FDA  Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting , the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus  clopidogrel , or  ticlopidine . Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the  ATLAS ACS TIMI 46   phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the ri...
Post a Comment
Read more